收藏网站
新闻中心
首页> 新闻中心 > 正文
FDA公布2010财政年度(2009.10.1-2010.09.30) 财政年度医疗器械收费案
发布时间:2009-08-21

FDA公布2010财政年度(2009.10.1-2010.09.30) 财政年度医疗器械收费案

 

2009101起到2010930止,FDA受理的新510(K)申请,FDA的审核费变更为USD4007;比2009财年增长了USD314

2010年医疗器械制造商年费变更为USD2008, 200910月开始到12月底止,FDA将征收所有注册制造商的2010年年费;

 

其他收费具体参加下表:

 

Table 1.--Medical Device Fees for FY 2010

----------------------------------------------------------------------------------------------------------------

                                Standard Fee, as a Percent

     Application Fee Type        of the Standard Fee for a     FY 2010 Standard Fee   FY 2010 Small Business Fee

                                   Premarket Application

 

----------------------------------------------------------------------------------------------------------------

Annual establishment (2010年度制造商年费)   Set in statute                   $2,008                      $2,008

 registration fee (to be paid

 by each establishment that

 is a manufacturer, a single-

 use device reprocessor, or a

 specification developer, as

 defined by 21 U.S.C.

 379i(13))

 

----------------------------------------------------------------------------------------------------------------

510(k) premarket notification                         1.84%                   $4,007                      $2,004

 Submission (510K审核费)

----------------------------------------------------------------------------------------------------------------

Premarket application (a PMA                 Set in statute                 $217,787                     $54,447

 submitted under section

 515(c)(1) of the act (21

 U.S.C. 360e(c)(1)), a PDP

 submitted under section

 515(f) of the Act, or a BLA

 submitted under section 351

 of the Public Health Service

 (PHS) Act (42 U.S.C. 262))

----------------------------------------------------------------------------------------------------------------

Premarket report (submitted                            100%                 $217,787                     $54,447

 under section 515(c)(2) of

 the act)

----------------------------------------------------------------------------------------------------------------

Efficacy supplement (to an                             100%                 $217,787                     $54,447

 approved BLA under section

 351 of the PHS Act)

----------------------------------------------------------------------------------------------------------------

Panel-track supplement                                  75%                 $163,340                     $40,835

----------------------------------------------------------------------------------------------------------------

180-day supplement                                      15%                  $32,668                      $8,167

----------------------------------------------------------------------------------------------------------------

Real-time supplement                                     7%                  $15,245                      $3,811

----------------------------------------------------------------------------------------------------------------

30-day notice                                          1.6%                   $3,485                      $1,742

----------------------------------------------------------------------------------------------------------------

513(g) (21 U.S.C. 360c(g))                            1.35%                   $2,940                      $1,470

 request for classification

 information

----------------------------------------------------------------------------------------------------------------

Annual Fee Type                                                                       ..........................

----------------------------------------------------------------------------------------------------------------

Annual fee for periodic                                3.5%                   $7,623                      $1,906

 reporting on a class III

 device

 

 

IRC编译整理

www.FDAChina.com